GERN News and Press, Geron Corporation From 12/26/23

2023-12-26 22:26:33 ET Summary Geron's Imetelstat shows promise for LR-MDS, especially for patients unresponsive to first-line treatments like ESAs, lenalidomide, or HMAs. Geron's financials are strong with a healthy current ratio and sufficient cash runway, but future funding nee...

2023-12-15 10:48:17 ET Penny stocks are the jittery nerves of the stock market – even minor news events can make them swing unpredictably. By definition, penny stocks are shares of companies traded below $5 per share and display extreme percentage changes from relatively insi...

Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from ...

2023-12-11 13:09:09 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics For further details see: Keros falls after mid-stage d...

IMpactMF is the first and only Phase 3 clinical trial to evaluate overall survival as the primary endpoint in R/R MF An interim analysis is expected in the first half of 2025, with a final analysis expected in the first half of 2026 Geron Corporation (Nasdaq: GERN), a late-sta...

2023-12-04 13:50:57 ET Summary Geron Corporation has submitted its New Drug Application (NDA) to the FDA for its lead candidate, imetelstat, for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes. The FDA has accepted Geron's NDA and wil...

2023-12-04 08:53:19 ET More on Geron Geron Corporation 2023 Q3 - Results - Earnings Call Presentation Geron Corporation (GERN) Q3 2023 Earnings Call Transcript Geron Corporation Stock: Another Buying Opportunity Geron GAAP EPS of -$0.08 beats by $0.02, revenu...

Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of ...

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a histo...

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2023 Healthcare Conference Tuesday, No...